Phio Pharmaceuticals Corp, a company operating within the Health Care sector and specializing in the Biotechnology industry, has recently garnered attention due to its participation in the Third Annual DealFlow Discovery Conference in 2026. This event underscores the company’s ongoing efforts to engage with key stakeholders and explore potential collaborations within the biotechnology landscape.
Phio Pharmaceuticals Corp is primarily focused on cancer immunotherapy, alongside developing treatments for other diseases. The company serves its customer base in the United States and is publicly traded on the Nasdaq stock exchange. Its official website, www.phiopharma.com , provides further information about its operations and product offerings.
Recent financial data reveals that Phio Pharmaceuticals Corp’s stock closed at $1.47 on February 16, 2026. This price is situated between the 52-week high of $4.19, achieved on November 2, 2025, and the 52-week low of $0.813, recorded on February 4, 2026. The significant fluctuation in stock price over the past year highlights the company’s volatile market performance.
The company’s market capitalization stands at $17,760,000 USD, reflecting its current valuation in the market. However, Phio Pharmaceuticals Corp’s financial metrics indicate challenges, with a negative price-to-earnings (P/E) ratio of -0.85. This negative P/E ratio suggests that the company is currently unprofitable, which is a critical factor for investors considering the company’s stock.
Despite the unprofitable earnings, the price-to-book (P/B) ratio of 1.80519 indicates that the market valuation is slightly above the book value. This suggests that investors may perceive potential in the company’s assets and future growth prospects, despite current financial challenges.
Overall, Phio Pharmaceuticals Corp’s recent activities and financial metrics paint a picture of a company navigating a complex market environment. Its participation in the DealFlow Discovery Conference highlights its commitment to advancing its research and development efforts, while its financial indicators suggest a need for strategic focus to achieve profitability and enhance market valuation.
